Issues surrounding therapeutic choices for hemophilia patients

Haematologica

Volumn 89, Issue 6, 2004, Pages 645-650

  Van Den Berg, H Marijke ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTHROPATHY; CENTRAL VENOUS CATHETER; CHILD; DISEASE SEVERITY; EDITORIAL; HEALTH CARE COST; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; LIFE EXPECTANCY;

DECISION MAKING; HEMOPHILIA A; HEMOPHILIA B; HUMANS; PREMEDICATION;

EID: 3042525116     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (59)

1. Fischer K, Van der Bom, Molho P, Negrier C, Mauser-Bunschoten EP, Roosendaal G, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002;8:1365-2516.
2. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A. A systematic review. Haemophilia 2003;9:418-435.
3. Lusher JM, Arkin S, Abildgaard, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia - safety, efficacy and development of inhibitors. N Engl J Med 1993;328:453-9.
4. Bray GL, Gomperts ED, Courter SG. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients. Blood 1994;83:2428-2435.
5. Ehrenforth S, Kreuz W. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339:594-8.
6. Schimpf K, Schwarz P, Kunschak M. Zero incidence of inhibitors in previously untreaed patients who received intermediate purity factor VIII concentrate or factor IX comples. Thromb Hemost 1995;73:553-5.
7. Rothschild C, Laurian Y, Satre EP, et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998;779-83.
8. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965;(Suppl 77):3-132.
9. Petrini P, Lindvall N, Egberg N, Blomback M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991;13:280-7.
10. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994;236:391-9.
11. van den Berg HM, Fischer K. Prophylaxis for severe hemophilia: Experience from Europe and the United States. Semin Thromb Hemost 2003;29:49-54.
12. Ljung R. Second Workshop of the European Paediatric Network for Haemophilia Management, 17-19 September 1998 in Vitznau/Switzerland, Haemophilia 1999;5:286-91.
13. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32.
14. Nilsson IM. Experience with prophylaxis in Sweden. Semin Hematol 1993;30(suppl 2):16-9.
15. Schramm W. Experience with prophylaxis in Germany. Semin Hematol 1993;30 (suppl 2):12-5.
16. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996;92:973-8.
17. van den Berg HM, Nieuwenhuis HK, Mauser-Bunschoten EP, Roosendaal G. Haemophilia prophylaxis in the Netherlands. Semin Hematol 1994;31(suppl 2):13-5.
18. Berntorp E, Michiels JJ. A healthy hemophilic patient without arthropathy: from concept to clinical reality. Semin Thromb Hemost 2003;1:5-10.
19. Fischer K, van der Bom JG, Prejs R, Mauser-Bunschoten EP, Roosendaal G, Grobbee DE, et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001;7:544-50.
20. National Hemophilia Foundation. MASAC recommendation concerning prophylaxis (prophylactic administration of clotting factor concentrate to prevent bleeding). #117. June 9, 2001.
21. Berntorp E. Viral safety measures of recombinant factor VIII products. Haematologica 2004;89(suppl. 1):3-7.
22. Perkins JL, Johnson VA, Osip JM, Christie BA, Nelson SC, Moertel CL, et al. The use of implantable venous access devices (IVADs) in children with hemophilia. J Pediatr Hematol Oncol 1997;19:339-44.
23. Ljung R. Central venous lines in haemophilia. Haemophilia 2003;9 (suppl 1):88-93.
24. Ljung R, van den Berg M, Petrini P, Tengborn L, Scheibel E, Kekomaki R, et al. Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr 1998;87:1051-4.
25. Blanchette VS, al-Musa A, Stain AM, Filler RM, Ingram J. Central venous access catheters in children with haemophilia. Blood Coag Fibrinolysis 1996;7(suppl 1):S39-S44.
26. Santagostino E, Gringeri A, Muca Perja M, Mannucci PM. A prospective clinical trial of implantable central venous access in children with haemophilia. Br J Haematol 1998;102:1224-8.
27. Miller K, Buchanan GR, Zappa S, Cochran C, Laufenberg J, Medeiros D, et al. Implantable venous access devices in children with hemophilia: a report of low infection rates. J Pediatr 1998; 132:934-8.
28. McMahon C, Smith J, Khair K, Liesner R, Hann IM, Smith OP. Central venous access devices in children with congenital coagulation disorders; complications and long-term outcome. Br J Haematol 2000;110:461-8.
29. van den Berg HM, Fischer K, Roosendaal G, Mauser-Bunschoten EP. The use of the Port-A-Cath in children with haemophilia - a review. Haemophilia 1998;4:418-20.
30. Li CH, Ou Y, Lee AC, So KT. Septic arthritis in hemophilia with central venous catheter: a case report. Pediatr Hematol Oncol 2000; 17:187-9.
31. Liesner RJ, Vora AJ, Hann IM, Lilleymann JS. Use of central venous catheters in children with severe congenital coagulopathy. Br J Haematol 1995;91:203-7.
32. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001;98:1727-31.
33. Ljung R, Petrini P, Lindgren AK, Berntorp E. Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia. Acta Paediatr 1992;811:918-20.
34. Girvan DP, deVeber LL, Inwood MJ, Clegg EA. Subcutaneous infusion ports in the pediatric patient with hemophilia. J Pediatr Surg 1994;29:1220-3.
35. Bohn RL, Avorn J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost 1998;79:932-7.
36. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 1996;129:424-31.
37. Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med 1998;244:515-22.
38. Feldman B, Rivard G, Israel S. Final results from the Canadian hemophilia dose escalation prophylaxis trial. XIX Congress of the International Society on Thrombosis and Haemostasis July 12-18, 2003. Birmingham, UK.[Abstract 0C219].
39. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999;105:1109-13.
40. van den Berg HM, Fischer K, Mauser-Bunschoten EP, Beek FJ, Roosendaal G, van der Bom JG, et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001;112:561-5.
41. Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, de Kleijn P, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002;99:2337-41.
42. Fischer K, van den Berg M. Prophylaxis for severe haemophilia: clinical and economical issues. Haemophilia 2003;9:376-81.
43. Brackmann HH, Eickhoff HJ, Oldenburg J, Hammerstein U. Long-term therapy and on-demand treatment of children and adolescents with severe haemophilias: 12 years of experience. Haemostasis 1992;22:251-8.
44. Petrini P. Treatment strategies in children with hemophilia. Pediatr Drugs 2002;4:427-437.
45. Manco-Johnson MJ, Nuss R, Funk S, Murphy J. Joint evaluation instruments for children and adults with haemophilia. Haemophilia 2000;6:649-57.
46. Kilcoyne RF, Nuss R. Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia 2000; 9(Suppl 1):57-64.
47. Ljung R. Paediatric care of the child with haemophilia. Haemophilia 2002;8:178-82.
48. Rand T, Trattnig S, Male C, Heinz-Peer G, Imhof H, Schneider B, et al. Magnetic resonance imaging in hemophilic children: value of gradient echo and contrast-enhancing imaging. Magn Reson Imaging 1999;17:199-205.
49. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999;5:145-54.
50. Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995;74:1402-6.
51. Lorenzo JI, Lopex A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001;113:600-3.
52. Suiter TM. First and next generation native rFVIII in the treatment of hemophilia A. What has been achieved? Can patients be switched safely? Semin Thromb Hemost 2002;26:277-83.
53. McMillan CW, Shapiro SS, Whitehurst, Hoyer LW, Rao AV, Lazerson J, et al. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988;71:344-8.
54. Lusher JM. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials. Haematologica 2000;85(Suppl 10):2-5.
55. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VII. N Engl J Med 1988;318:947-50.
56. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912-8.
57. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEI-BA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997;77:1113-9.
58. Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000;95: 1324-9.
59. Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 2000;95:564-8.